Company intelligence / Profile preview
Ansun Biopharma
San Diego, California, United Statesansunbiopharma.com ↗
- Ownership
- Private
- Employees
- ~25
- Development stage
- Phase 3
01
Overview
Ansun's lead product DAS181 is currently in Phase 3 clinical trials for treatment of lower respiratory tract parainfluenza infection in immunocompromised patients. The Phase 2 study showed potential clinical benefits for immunocompromised patients with PIV in lower lung infection who are receiving supplemental oxygen.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Recombinant fusion proteinsRecombinant therapeutic proteins
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Ansun Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ansun Biopharma.